Cardiovascular disease and gene therapy research by Tenaya Therapeutics

  • Ashutosh Sureka
  • 06.08.2026
Tenaya Therapeutics unveils second quarter financial results and updates on business programs
Tenaya Therapeutics released its second quarter financial results alongside updates on its business operations and program development. The company did not disclose specific financial figures or ...
  • Andreas Kristo
  • 03.06.2026
Tenaya Therapeutics sees advances in symptom relief and cardiac hypertrophy measures
Tenaya Therapeutics has released new interim results from its ongoing clinical trial of TN-201, pointing to promising improvements in patient symptoms, functional capacity, and measures of cardiac ...
  • Eugene Komchuk
  • 29.05.2026
Tenaya Therapeutics CEO to present at Jefferies Global Healthcare Conference on June 4
Tenaya Therapeutics announced that its CEO, Faraz Ali, will deliver a presentation at the Jefferies Global Healthcare Conference. The event will take place on Thursday, June 4, 2026, at 3:10 p.m. ...
  • Yulia Slavina
  • 15.05.2026
Tenaya Therapeutics presents new RIDGE-1 trial results showing arrhythmia reduction in PKP2-associated ARVC
Tenaya Therapeutics unveiled interim results from its RIDGE-1 Phase 1b/2 trial at #ASGCT, indicating consistent reductions in arrhythmias among adults with PKP2-associated arrhythmogenic right ...
  • Eugene Komchuk
  • 13.05.2026
Tenaya Therapeutics partners on parent attitudes survey for gene therapy in pediatric cardiomyopathy
Tenaya Therapeutics has joined forces with prominent pediatric advocacy group CCFheartkids and treatment center DdccLinic to conduct a survey among parents of children with cardiomyopathy ...
  • Olga Shendetskaya
  • 12.05.2026
Eugene Braunwald legacy in HCM research honored by Tenaya Therapeutics
Tenaya Therapeutics joined the scientific community in paying tribute to Eugene Braunwald, MD, often called the father of modern cardiology, for his pioneering work in hypertrophic cardiomyopathy ...